CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Identa Corp. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Identa Corp.
5 Kiriat Hamada St.
The Luz Bldg.
Phone: 972 52 6554487p:972 52 6554487 Har Hotzvim, Jerusalem  91450  Israel Ticker: IDTA IDTA

Business Summary
Identa Corp. develops, manufactures, and distributes proprietary on-site drugs-of-abuse testing products (chemical kit) for the professional and civil markets. The Company's products include rapid test kits (substance only) for the detection of Marijuana/Hashish, Ecstasy, Cocaine/Crack, and Heroin.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Business Names
Business Name
Identa Ltd
IDTA

General Information
Stock Exchange: OTC
Fax Number: 972-2-9716875


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024